Dudediligence.

Ginkgo Bioworks Holdings, Inc

DNANYSE · Biological Products, (No Diagnostic Substances)
Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

63.7M

on 2026-06-30, from 50.8M on 2024-03-31 10-Q ↗

Earlier counts are adjusted for the 1-for-40 reverse split; each bar's tip shows the count as filed.

a raise that quarter, at its price

Newest

Filed

S-3 of 2025-08-07. Size not read. 1 prospectus supplement filed under it since. S-3 ↗

$100.0M

Allen, agreement of 2025-09-04. No at-the-market sales statement read from a 10-Q or 10-K. 8-K ↗

Warrants

The 10-Q filed 2026-08-06 is not read yet.

Cash

2 quarters

$84.5M on 2026-06-30 ÷ $42.6M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
DateWhatSharesPriceGrossFiling
2025-09-04Public offeringnot readnot readnot read424B5 ↗